Total amount: € 0,00
HOW TO ORDER
MEDICINA DELLO SPORT
A Journal on Sports Medicine
Official Journal of the Italian Sports Medicine Federation
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,163
Medicina dello Sport 2007 December;60(4):595-603
language: English, Italian
Treatment of chronic patellar tendinosis with buffered platelet rich plasma: a preliminary study
Volpi P. 1, Marinoni L. 1, Bait C. 1, De Girolamo L. 1, 2, Schoenhuber H. 1
1 Sports Traumatology and Arthroscopic Surgery Unit, Galeazzi Orthopaedics Institute, IRCCS, Milan, Italy
2 Department of Medical Pharmacology, Faculty of Medicine, University of Milan, Galeazzi Orthopaedics Institute, IRCCS, Milan, Italy
Eight athletes considering surgical intervention for chronic patellar tendinosis that was recalcitrant to conservative physical therapy and a variety of non-operative treatments were recruited into the study. Following pre-injection MRI imaging and VISA score assessment, patients received a single injection of PRP (Platelet-Rich Plasma). Patients were given individualized rehabilitation protocols and followed until a final assessment at 120 days post-injection.
Seven of the eight patients were assessed at the final follow-up, with all of them demonstrating an improvement on the VISA score. One patient elected to have surgical intervention prior to the final follow-up and was not included in the analysis. The average VISA score at the final assessment was 75.0 compared to a pre-injection average of 39.25. This represented a 91% of average improvement in the VISA score (p<0.001). MRI images at the final follow-up demonstrated a noticeable reduction in irregularity of the affected tendon compared to pre-injection images for 80% of the treated tendons.
Treatment of chronic patellar tendinosis in a series of athletes resulted in a statistically significant improvement in VISA score for seven of the eight patients treated. Pre and post-injection MRI demonstrated reduced irregularity in eighty percent of the injected tendons. Further evaluation of this treatment is warranted.